Visual Dysfunction in Diabetes: The Science of Patient Impairment and Health Care

ISBN-13: 9781493961689 / Angielski / Miękka / 2016 / 379 str.

Joyce Tombran-Tink; Colin J. Barnstable; Thomas W. Gardner

Opis

This book helps readers understand the impact of vision impairment in people living with diabetes, rather than seeing diabetic retinopathy
solely as a medical problem, and explores what we know and don't know about the ways diabetes affect the eye.

Recenzje

"It succeeds in summarizing recent advancements in our knowledge in the field with a well illustrated presentation, up-to-date references, and an authorship selected from an international group of respected investigators with proven contributions to the field. ... It could be recommended as a reference for anyone interested in the basic mechanisms of the disease, its ocular manifestations, and treatment options." (Radouil Tzekov, Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 253 (6), June, 2015)

Spis treści

Introduction

Diabetic Retinopathy – what we know, don’t know, and need to know – Tom Gardner

Living with Diabetic Retinopathy

Ch. 1 A Patient’s viewpoint: Heather Stuckey

Ch. 2 What patients with diabetes see—and don’t see: subjective and objective visual function

changes - Shelly Boyd

Ch. 3 How do I know I have diabetic retinopathy – a clinician’s view? - David Quillen

Prevalence, Public Awareness, and Screening Methods

Ch. 4 Epidemiology & Economics - John Javitt

Ch. 5 Correlation between the presence and severity of diabetic retinopathy in families with diabetes

- Victor Gonzalez

Ch. 6 Increasing public awareness of the diabetes endemic – Ian Constable

Ch. 7 Nutrition and diabetes– David Nathan

Ch. 8 Diabetic retinopathy screening – progress and complications - Peter Scanlon

 

Diagnosing Diabetic Retinopathy

Ch. 9 Measurements of retinal blood flow, vascular leakage, and oxygenation – Einer Stefansson

Ch. 10 Optical imaging - Confocal microscopy to detect retinal vasculature – Martin Friedlander

Ch. 11 Structural imaging – OCT – M. Larsen

Ch. 12 Functional imaging - ERG - Anthony Adams

 

How Diabetes Affects the Eye

Ch. 13 Clinical phenotypes (reclassification) – J. Cunha-Vaz

Ch. 14 Vascular changes – David Antonetti & Tom Gardiner (Belfast)

Ch. 15 Neuronal ch

anges - Alistair Barber/Greg Jackson

Ch. 16 Inflammatory changes - Mark Tso

Ch. 17 Other Ocular Complications of Diabetes - Shoja MR

 

New Approaches to Diabetic Retinopathy

Ch. 18 New insights in the pathogenesis of diabetic retinopathy using a proteomic approach – Retina -

Quin GG

Ch. 19 Vitreous proteomics – Ed Feener

Ch. 20 Genomics - Bill Freeman

Ch. 21 Genome-wide linkage analyses to identify Loci for diabetic retinopathy - Kang Zhang (Utah)

Risk Factors

Ch. 22 Diabetic retinopathy correlates with increased incidence of cardiovascular events -Cheung N

Ch. 23 Pregnancy and rate of progression of diabetic retinopathy – Sheth BP

 

Molecular Mechanisms that Could Trigger Visual Dysfunction in Diabetes

Introduction - Tom Gardner

Ch. 24 Inflammation in the early pathogenesis of diabetic retinopathy —beauty and beast. - Chris Norbury (Hershey)

Ch. 25 Oxidative stress and diabetic retinopathy. - Catherine Whiteside

Ch. 26 Glucose induced cellular signaling in diabetic retinopathy – Chakrabarti S

Ch. 27 The AGE/RAGE axis in early diabetic retinopathy - Schmidt AM

Ch. 28 Proteases and the retinal vasculature (and maybe the whole retina!) – Arup Das.

Ch. 29 IGFBP3 and retinal vessel growth. Smith LE

Ch. 30 PEDF, VEGF, CTGF review – JX Ma

Ch. 31 A decrease in the expression of somatosta

tin is an early event in diabetic retinopathy -

Carrasco E

Ch. 32 Connective tissue and connective tissue growth factor in diabetic retinopathy - Schlingemann

RO

Ch. 33 Molecular regulation of endothelial cell tight junctions and the blood retinal barrier - Antonetti

DA

Ch. 34 Pericytes and diabetic retinopathy - Puro DG

Ch. 35 Leukostasis - Adamis, AP

Ch. 36 Adhesion molecules (ICAM-1 and VCAM-1) and diabetic retinopathy in type 2 diabetes. -

Khalfaoui T,

Ch. 37 Azurocidin as a Permeability Factor in the Retina - Hafezi-Moghadam A

Ch. 38 Retinal arteriolar hemodynamic response to a combined isocapnic hyperoxia and glucose

provocation in early sight-threatening diabetic retinopathy. - Devenyi RG.

Ch. 39 Urinary 8-hydroxydeoxyguanosine (8-OHdG) levels in diabetic retinopathy patients. - Steve

Abcouwer

Ch. 40 Tyrosine nitration in the molecular mechanisms of diabetic retinopathy. - Crabb JW

Limiting Vision Loss - Experimental Therapies

Introduction - Tom Gardner

Vascular Control

Ch. 41 Ranibizumab for macular edema in diabetes – Quan Dong Nguyen

Ch. 42 Bevacizumab for PDR - Qin H

Ch. 43 Capillary degeneration in the early stages of diabetic retinopathy. Kern TS

Ch. 44 Renin-angiotensin system in the eye - Jennifer Wilkinson-Berka

Ch. 45 Statins and the BRB –Ruth Caldwell

 

Neuro

nal Control

Ch. 46 Treatment of hypoxia-induced retinopathy with targeted proapoptotic peptidomimetic in a

mouse model of disease. Lahdenranta J

Ch. 47 Intravitreal Injection of Erythropoietin Protects both Retinal Vascular and Neuronal Cells in

Early Diabetes - Zhang J and Xu GT

Inflammatory Control

Ch. 48 Glial cell-derived cytokines attenuate the breakdown of vascular integrity in diabetic

retinopathy. Sawada N

Ch. 49 Ruboxistaurin shows promise as an oral treatment for diabetic retinopathy - Clarke M, Dodson

PM.

Ch. 50 Intravitreal triamcinolone acetonide for diabetic retinopathy - Jonas JB

Ch. 51 Aptamers that bind PDGF-B are a potential treatment for proliferative retinopathies. Akiyama H

Ch. 52 Effect of R-(+)-alpha-lipoic acid on experimental diabetic retinopathy - Lin J

Regenerative Approaches

Ch. 53 Islet Cell/stem cell transplantation - Warnock GL (Canada)

Future Directions

Ch. 54 How do we improve the translational research process? What do we need to know? Barbara

Araneo

 

Conclusion – Tom Gardner

Blurb

An exciting contribution to the field, Visual Dysfunction in Diabetes: The Science of Patient Impairment and Improvement is designed with two overriding objectives: to help readers understand the impact of vision impairment in people living daily with diabetes rather than considering diabetic retinopathy solely as a medical problem, and to explore what we know and don't know about the ways diabetes affect the eye.  With the plethora of new information being generated, there are still a series of fundamental questions that must be addressed if effective treatments for diabetic retinopathy are to be found and applied.  Developed by a renowned group of authorities, Visual Dysfunction in Diabetes: The Science of Patient Impairment and Improvement offers responses and context for a range of questions, such as: do metabolic factors beyond glucose contribute to vision-threatening diabetic retinopathy? If so, how do these lead to vision impairment?  Is diabetic retinopathy a response to systemic metabolic abnormalities or are there unique ocular problems related to insulin resistance? What is the relationship between the neural, vascular, and inflammatory abnormalities in diabetic retinopathy? Do they represent a pathological cascade induced sequentially or simultaneous responses to one or more metabolic perturbations?  The authors note that if we do not address these types of questions, it is possible that the long process of developing new therapeutic

s will target only one arm of the pathology and leave the retina open to damaging consequences of the others. State-of-the-art, comprehensive, and an invaluable addition the research and clinical literature, Visual Dysfunction in Diabetes: The Science of Patient Impairment and Improvement offers guidance and a significant step toward new scientific approaches that can lessen the devastating vision impairment associated with diabetes.